AnaptysBio (NASDAQ:ANAB)‘s stock had its “buy” rating reiterated by stock analysts at Robert W. Baird in a report issued on Friday. They presently have a $144.00 target price on the biotechnology company’s stock, up from their previous target price of $81.00. Robert W. Baird’s price objective points to a potential upside of 30.38% from the company’s previous close.
Other analysts also recently issued reports about the stock. Zacks Investment Research downgraded shares of AnaptysBio from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Royal Bank of Canada increased their price target on shares of AnaptysBio to $108.00 and gave the company an “outperform” rating in a research report on Monday, December 18th. SunTrust Banks initiated coverage on shares of AnaptysBio in a research report on Wednesday, November 15th. They issued a “buy” rating and a $115.00 price target on the stock. Credit Suisse Group increased their price target on shares of AnaptysBio from $38.00 to $85.00 and gave the company an “outperform” rating in a research report on Tuesday, October 10th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $76.00 price target (up from $35.00) on shares of AnaptysBio in a research report on Friday, October 13th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. AnaptysBio has a consensus rating of “Buy” and a consensus price target of $96.33.
AnaptysBio (ANAB) opened at $110.45 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77. AnaptysBio has a one year low of $15.17 and a one year high of $116.67.
AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.02. sell-side analysts forecast that AnaptysBio will post -1.72 EPS for the current year.
A number of hedge funds have recently made changes to their positions in the business. Schwab Charles Investment Management Inc. raised its holdings in AnaptysBio by 128.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 74,940 shares of the biotechnology company’s stock worth $7,548,000 after buying an additional 42,094 shares during the period. Perceptive Advisors LLC raised its holdings in AnaptysBio by 3.2% during the 3rd quarter. Perceptive Advisors LLC now owns 982,269 shares of the biotechnology company’s stock worth $34,330,000 after buying an additional 30,000 shares during the period. VHCP Management II LLC acquired a new stake in AnaptysBio during the 3rd quarter worth approximately $5,856,000. Evercore Wealth Management LLC acquired a new stake in AnaptysBio during the 3rd quarter worth approximately $100,000. Finally, California State Teachers Retirement System raised its holdings in AnaptysBio by 104.2% during the 3rd quarter. California State Teachers Retirement System now owns 19,400 shares of the biotechnology company’s stock worth $678,000 after buying an additional 9,900 shares during the period. Hedge funds and other institutional investors own 75.48% of the company’s stock.
WARNING: This article was published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.truebluetribune.com/2018/01/19/anaptysbio-anab-stock-rating-reaffirmed-by-robert-w-baird.html.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.